Gestern hat CO.DON vom Schweizer Heilmittelinstitut (Swissmedic) die Zulassung für Spherox erhalten. Damit ist es CO.DON zukünftig erlaubt, Spherox in Schweizer Kliniken für autologe Zelltherapien zur minimalinvasiven Reparatur von Knorpeldefekten im Knie anzubieten. Da mit den Schweizer Krankenpflegeversicherungen bereits die Erstattung für die Methode der körpereigenen Knorpelzelltransplantation vereinbart wurde, kann CO.DON Angabe gemäß zeitnah mit der Produktvermarktung beginnen. Mit ersten Umsätzen dürfte nach unserer Einschätzung schon in diesem Jahr zu rechnen sein. Laut Angaben von CO.DON liegt der erstattungsfähige Preis in der Schweiz im Rahmen des europäischen Preisniveaus, nach unserer Einschätzung im hohen vierstelligen Euro-Bereich. Abgesehen von der ökonomischen Bedeutung besteht die besondere Wertigkeit der Zulassung aus unserer Sicht darin, dass CO.DON damit neben der bereits bestehenden EU-weiten Zulassung nun auch die erste Zulassung des Gelenkknorpelprodukts Spherox außerhalb des EU-Wirtschaftsraumes erhalten hat. Wir bestätigen unser aus einem dreiphasigen DCF-Entity-Modell ermitteltes Kursziel auf Sicht von 24 Monaten von EUR 9,60 je Aktie (Base Case-Szenario). Aus einer Monte-Carlo-Szenarioanalyse ergeben sich unverändert Kursziele zwischen EUR 12,60 (Best Case) und EUR 6,00 (Worst Case). Gegenüber dem letzten Schlusskurs von EUR 4,39 ergibt sich im Base Case-Szenario ein von uns erwartetes Kurspotenzial von 118,7%. Wir bestätigen dementsprechend unser Buy-Rating für die Aktien der CO.DON AG.
Co.don AG is a Germany-based company that is active in the tissue engineering and regenerative medicine industry. The Company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal particular cartilage defects, lumbar disc herniation, non-union fractures and dental disorders. Those include co don chondrotransplant, which is used for cartilage treatment, particularly in the knee area; co don chondrosphere, which is a three-dimensional articular cartilage cultivated outside of the body; co don chondrotransplant DISC, for the regeneration of intervertebral discs, and co don osteotransplant DENT, which is an autologous bone cell transplant for dental applications. The Company is active domestically and in other European countries.
Founded in 2010, Sphene Capital is a German based pure-play research house offering state-of-the-art research and evaluation services to European small- and mid-caps by avoiding typical conflict of interests of traditional investment banks.
As a general rule, analysts of Sphene Capital strive to understand companies better than any other analyst or investor before publishing their initiation reports. Therefore, the comprehensive initiation research reports comprise of 50-80 pages, including an extensive analysis of the value chain of the IPO candidate, its unique selling proposition, an elaborate analysis of suppliers and clients, a thorough SWOT analysis, a commercial due diligence (i. e. market and competitive analysis), an integrated financial forecast model and a profound company valuation (both DCF methodology and peer group multiples). Before publication, each of Sphene Capital’s research report will be double-checked by a fellow research colleague (“Four-eyes-principle”), ensuring highest quality and avoiding careless mistakes.
After initiation of research coverage, Sphene Capital publishes regular updates of 12-30 pages following relevant news flow from the issuer or major peers, f. ex. after acquisitions or after publication of quarterly results.
Due to Sphene Capital’s extensive experience in equity and bond research, the team has established longstanding contacts to all relevant market players, i. e. institutional investors, family offices and high net-worth individuals as well as journalists. To each of these groups, Sphene Capital’s research analysts have regular contacts during analyst and management roadshows or via daily phone calls. Finally, analysts publish articles in selected stock markets magazines and websites in which the analysts help issuers to improve their popularity on the German capital markets.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.